

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Title:

Reasons for non-attendance to cervical cancer screening and acceptability of HPV self-sampling among Bruneian women: A cross-sectional study.

Authors:

Liling Chaw^{1*}, Shirley HF Lee¹, Nurul Iffah Hazwani Ja'afar¹, Edwin Lim², Roslin Sharbawi³

Affiliations:

- 1) PAPRSB Institute of Health Sciences, Gadong, Brunei Darussalam.
- 2) Histopathology Department, RIPAS Hospital, Ministry of Health, Brunei Darussalam
- 3) Community Maternal Health Service, Department of Health Services, Ministry of Health, Bandar Seri Begawan, Brunei Darussalam

*** Corresponding Author:**

Email: liling.chaw@ubd.edu.bn (LC)

Running title:

Reasons for cervical cancer screening non-attendance and HPV self-sampling acceptability in Brunei

Number of words: 327 words (abstract), 4387 words (manuscript, excluding references)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27 **Abstract**

28

29 **Objective:** Uptake for cervical cancer screening remains well below the recommended rate of 80%.

30 We conducted a pilot study to determine the reasons for non-attendance and explore their

31 acceptance of human papillomavirus (HPV) self-sampling as an alternative to Pap test.

32

33 **Methods:** A two-part cross-sectional study was conducted at a health centre in Brunei, from January

34 to December 2019. Women who were eligible for a Pap test but who either never or did not have

35 one within the past four years were conveniently recruited. Participants were first asked to

36 complete a paper-based survey on their reasons for screening non-attendance, and then invited for

37 HPV self-sampling. Results were analysed using descriptive and inferential statistics.

38

39 **Result:** We enrolled 174 screening non-attendees, out of which 97 (55.7%) also participated in HPV

40 self-sampling. The main reasons for not attending Pap test screening were fear of bad results

41 (16.1%, n = 28); embarrassment (14.9%, n = 26) and lack of time due to home commitments (10.3%,

42 n = 18). When compared to those who agreed to participate in HPV self-sampling, those who

43 declined were significantly older ($p = 0.002$) and less likely to agree that they are susceptible to

44 cervical cancer ($p = 0.023$). They preferred to receive Pap-test related information from healthcare

45 workers (59.0%, n = 155), social messaging platforms (28.7%, n = 51) and social media (26.4%, n =

46 47). HPV self-sampling kits were positively-received, where > 90% agreed on its ease and

47 convenience. Nine of 97 participants (9.3%) tested positive for hr-HPV, out of which eight were non-

48 16/18 HPV genotypes.

49

50 **Conclusion:** Our findings suggest that promoting knowledge on cervical cancer, the benefits of

51 screening and clarifying any misconceptions of Pap test results would help increase screening uptake

52 among Bruneian non-attendees. Response to HPV self-sampling was highly positive, implying its
53 receptiveness in the local setting. Our high detection of non-16/18 HPV genotypes suggest high
54 prevalence of other hr-HPV genotypes in Brunei. Larger studies can be conducted to further validate
55 our findings.

56

57

58

59 **Keywords:** Cervical cancer screening, HPV self-sampling, women's health, Brunei

60 **Introduction**

61

62 Cervical cancer is highly preventable but still remains one of the most common cancers among
63 women worldwide, accounting for 6.6% of all female cancer deaths in 2018 [1]. Cervical cancer
64 screening has drastically reduced the incidence of invasive cervical cancer in countries that have
65 implemented such screening programmes [2], which traditionally involves the use of the standard
66 Papanicolaou (Pap) test. However, as specific high-risk human papillomavirus subtypes (hr-HPV) are
67 known to be a causative agent, the use of HPV self-sampling is becoming either an alternative or a
68 complement to the Pap test to increase screening uptake rate [3], particularly to promote women's
69 participation among screening non-attendees [4].

70

71 HPV self-sampling were found to be highly acceptable among non-attendees [5,6]. Repeated HPV
72 self-sampling and testing were shown to increase screening uptake [3,4,7], and also resulted in at
73 least two-fold higher detection rate of high-grade cervical intraepithelial neoplasia (CIN2+) when
74 compared to Pap test [8,9]. In addition, HPV self-sampling results exhibit similar sensitivity and
75 specificity compared to results from samples taken by trained professionals [10]. At the national
76 level, early detection through organised screening had been shown to reduce cervical cancer
77 morbidity and mortality in countries such as the United Kingdom and Australia [11,12]. Both
78 countries have further strengthened their national cervical cancer screening programme by
79 replacing cytological test with HPV test as the primary screening test.

80

81 Brunei Darussalam (population 459,500) is a small Southeast Asian country with a predominant
82 Muslim population and a crude birth rate of 15.3 per 1,000 population [13]. Within this region, it has
83 one of the highest age-standardised incidence rate (ASR) for cervical cancer: 20.6 in Brunei when
84 compared to 10.5 and 7.7 in Malaysia and Singapore, respectively [14]. Brunei has initiated a
85 national cervical cancer prevention and control programme since 2009, which include setting up the

86 National Pap Test Registry, organising cervical screening through periodic mail invitations for
87 sexually-active women aged 20 to 65 years, replacing the conventional Pap test with liquid-based
88 cytology, and initiating HPV vaccination for school-aged female adolescents [15]. However, despite
89 cervical screening being offered free of charge, the national screening coverage rate remains low at
90 44% in 2018 (unpublished data). Non-attendees of cervical screening are at increased risk of
91 developing cervical cancer; hence the importance of reaching these women [16]. Reasons for
92 screening non-attendance can also vary across settings [17,18].

93

94 With Brunei's relatively high incidence of cervical cancer and low screening uptake, we conducted a
95 pilot study to explore the reasons behind non-attendance and assess the acceptability of HPV self-
96 sampling as a possible alternative to the Pap test among non-attendees. Study findings could be
97 used to strategise ways to improve screening coverage and provide preliminary evidence towards
98 implementing HPV testing as the primary screening test for cervical cancer in Brunei.

99

100 **Methods**

101

102 *Study design and data collection*

103

104 We conducted a two-part cross-sectional survey at Jubli Perak Sengkurong Health Center (JPSHC),
105 from January to December 2019. JPSHC is a government-funded health centre located in Brunei-
106 Muara District, where the majority (69.3%) of the country's population resides. This centre provides
107 primary health care services to Mukim Sengkurong, a sub-district with about 32 000 people from
108 various socioeconomic backgrounds.

109

110 Eligible women attending either the outpatient or child health clinic were conveniently recruited by
111 triage nurses. The inclusion criteria were married or ever married Bruneian women between 20 and

112 65 years old, who never had a Pap test or did not have a Pap test within the last 4 years, and who
113 can comprehend Brunei-Malay or English language. Women who were either pregnant, have had
114 total hysterectomy, or with a history of malignancies were excluded.

115

116 Following recruitment, potential participants were referred to an assigned research focal person
117 based at JPSHC. The participants were informed of the study objectives and of the two study parts;
118 the first involving a set of self-administered questionnaires on reasons for non-attendance to routine
119 cervical screening (Q1), and the second (optional) part involving HPV self-sampling to be performed
120 at a later date and completing a second self-administered questionnaire on their acceptability of the
121 self-sampling procedure (Q2).

122

123 Participants who consented to the first part of the study were asked to complete Q1 onsite. They
124 were then given an envelope containing information on the second optional study and an instruction
125 leaflet on the HPV self-sampling procedure. Within two weeks, they were contacted by the focal
126 person regarding their decision to participate in the second part of the study. Those who agreed to
127 participate were given an appointment to JPSHC. On the appointment day, a trained nurse first
128 explained the self-sampling procedure with the aid of an online instructional video, and answered
129 any questions or concerns. Then, participants were given a self-sampling kit and asked to perform
130 the self-sampling procedure in the clinic. After completing the procedure, the participants were
131 invited to complete Q2.

132

133 *Questionnaires used*

134

135 Two bilingual paper-based questionnaires (Brunei-Malay and English language) were used: one on
136 the reasons for non-attendance (Q1) and another on their acceptability of the self-sampling
137 procedure (Q2). Both questionnaires were adapted from similar studies [19,20]. They were first

138 translated to Brunei-Malay language by native speakers, and then back-translated to check for
139 inconsistencies in comprehension. Both questionnaires were also pre-tested on six eligible women
140 to assess if the questions can be easily understood. Responses from pre-testing were not included in
141 the main analysis.

142

143 Q1 consists of 19 questions on the participant's socio-demographics; reasons for not getting Pap
144 test; attitude and knowledge on cervical cancer; and lastly, preferred sources to acquire information
145 about Pap test. From a prepared list of 16 options, participants were asked to select one ("Major"
146 reason) or more reasons (categorized as "Minor" reasons) for not attending the screening
147 programme. Responses for questions on their attitude and knowledge on cervical cancer were
148 assessed using a five-point Likert scale, ranging from "Strongly Agree" to "Strongly Disagree". Q2
149 consists of 12 five-point Likert scale questions (ranging from "Strongly Agree" to "Strongly Disagree")
150 on their experiences and opinions of the self-sampling kit.

151

152 *Self-sample handling and laboratory testing*

153

154 Swabs collected from the self-sampling kits were sent to an overseas laboratory (at BNH hospital,
155 Thailand) for hr-HPV testing. The self-sampling device used was the Evalyn® brush from Rovers
156 Medical Devices. Upon receipt at the testing laboratory, the dry Evalyn® brush was suspended in
157 SurePath medium from which a sample was obtained for the identification of the presence of hr-
158 HPV using the cobas HPV test (Roche, USA). Cobas HPV tests are automated qualitative *in vitro* tests
159 for the detection of HPV DNA in patient specimens. The tests utilize amplification of target DNA by
160 polymerase chain reaction (PCR) and nucleic acid hybridization for the detection of 14 hr-HPV types
161 (namely genotypes 16, 18, and 12 pooled hr-HPV genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66
162 and 68) in a single analysis. Results obtained from this test can be categorized into four groups:
163 Negative, HPV-16 positive, HPV-18 positive, and positive for non-16/18 HPV genotypes.

164

165 *Clinical management of hr-HPV positive participants*

166

167 We adopted the cytology triage strategy for HPV self-sampling participants [21]. Participants with hr-
168 HPV positive results were invited for an immediate clinic-based cytology triage test. Those found to
169 have negative cytology results were invited for a repeat cytology triage test after six months. Those
170 with second negative results were returned to routine cervical screening recall. Participants with any
171 positive cytology result (defined as with Atypical Squamous Cells of Undetermined Significance or
172 worse) were referred for colposcopic examination.

173

174 *Statistical analysis*

175


176 Descriptive statistics was conducted to characterize the socio-demographic characteristics of the
177 study population, their reasons for not attending screening, their attitudes and preference for
178 information access on such screening, as well as responses from Q2. Mann-Whitney and Fisher's
179 exact tests were used to assess significant differences in sociodemographic characteristics between
180 women who agreed and women declined to proceed to the HPV self-sampling part of the study.
181 Responses for questions with the five-point Likert scale were categorized into three categories
182 (agree, neutral, and disagree), and those with missing values were classified as neutral. Analysis was
183 conducted using R ver. 3.6 [22]. Ethics approval was obtained from the Medical and Health Research
184 and Ethics Committee (MHREC), Ministry of Health, Brunei Darussalam [Reference no.
185 MHREC/MOH/2018/9(2)].

186

187 **Results**

188

189 A total of 174 eligible women were enrolled into the study from January to December 2019, out of
190 which 97 (55.7%) also participated in HPV self-sampling (Figure 1). Their median age was 45 years,
191 ranging between 23 and 65 years (Table 1). The participants were mainly of Malay ethnicity (92.5%,
192 n = 161), married (90.2%, n = 157), and had three or more births (60.3%, n = 105). More than half of
193 the participants had their last Pap test performed between 4 and 10 years ago (52.3%, n = 91) and
194 have never received the HPV vaccine (54.6%, n = 95). There were significant differences between
195 those who agreed and declined to participate in HPV self-sampling: those who declined were
196 significantly older ($p = 0.002$) and more likely to have their last Pap test performed more than 10
197 years ago ($p = 0.031$).
198



199
200 Figure 1. Flowchart of study participants at JPHSC, Brunei (Jan – Dec 2019)
201

Characteristics		Total study population (n = 174) n (%)	Joined self-sampling (n = 97) n (%)	Declined self-sampling (n = 77) n (%)	p-value
Median age in years (IQR)		45 (15.25)	41.0 (17)	49.0 (14.5)	0.002*
Age-group (in years)	20 - 24	3 (1.7)	3 (3.1)	0 (0.0)	0.018*
	25 - 29	20 (11.5)	15 (15.5)	5 (6.5)	
	30 - 34	14 (8.1)	10 (10.3)	4 (5.2)	
	35 - 39	28 (16.1)	18 (18.5)	10 (13.0)	
	40 - 44	18 (10.3)	11 (11.3)	7 (9.0)	
	45 - 49	27 (15.5)	12 (12.4)	15 (19.5)	
	50 - 54	35 (20.1)	15 (15.5)	20 (26.0)	
	55 - 59	14 (8.1)	10 (10.3)	4 (5.2)	
	> 60	13 (7.5)	3 (3.1)	10 (13.0)	
	Missing	2 (1.1)	0 (0.0)	2 (2.6)	
Race	Malay	161 (92.5)	90 (92.8)	71 (92.2)	0.752
	Chinese	6 (3.5)	4 (4.1)	2 (2.6)	
	Other	7 (4.0)	3 (3.1)	4 (5.2)	
Education level	Primary school	16 (9.2)	10 (10.3)	6 (7.8)	0.396
	Secondary school	96 (55.2)	49 (50.5)	47 (61.0)	
	College / university	57 (32.7)	35 (36.1)	22 (28.6)	
	Missing	5 (2.9)	3 (3.1)	2 (2.6)	
Marital status	Married	157 (90.2)	91 (93.8)	66 (85.7)	0.15
	Divorced	8 (4.6)	2 (2.1)	6 (7.8)	
	Widowed	9 (5.2)	4 (4.1)	5 (6.5)	
Occupation	Housewife	64 (36.8)	39 (40.2)	25 (32.4)	0.087
	Government employee	67 (38.5)	41 (42.3)	26 (33.8)	
	Private employee	31 (17.8)	13 (13.4)	18 (23.4)	
	Retired	9 (5.2)	3 (3.1)	6 (7.8)	
	Unemployed	1 (0.6)	1 (1.0)	0 (0.0)	
	Other	2 (1.1)	0 (0.0)	2 (2.6)	
Monthly household income	< \$500	27 (15.5)	15 (15.5)	12 (15.6)	0.498
	\$500 < \$999	27 (15.5)	12 (12.4)	15 (19.5)	
	\$1000-\$1999	40 (23.0)	22 (22.7)	18 (23.4)	
	\$2000-\$2999	19 (10.9)	14 (14.3)	5 (6.5)	
	\$3000-\$5000	24 (13.8)	15 (15.5)	9 (11.7)	
	>\$5000	3 (1.7)	2 (2.1)	1 (1.3)	
	Missing	34 (19.5)	17 (17.5)	17 (22.0)	
Number of births	0	27 (15.5)	17 (17.5)	10 (13.0)	0.103
	1	19 (10.9)	14 (14.4)	5 (6.5)	


	2	22 (12.1)	14 (14.4)	7 (9.1)	
	3 or more	105 (60.3)	51 (52.6)	54 (70.1)	
	Missing	2 (1.2)	1 (1.1)	1 (1.3)	
Last Pap test done	Never	41 (23.6)	29 (29.9)	12 (15.6)	0.031*
	4-10 years	91 (52.3)	48 (49.5)	43 (55.8)	
	> 10 years	36 (20.7)	15 (15.5)	21 (27.3)	
	Missing	6 (3.4)	5 (5.1)	1 (1.3)	
Completed HPV vaccination	Never	95 (54.6)	50 (51.6)	45 (58.4)	0.483
	Yes	27 (15.5)	16 (16.5)	11 (14.3)	
	No	41 (23.6)	26 (26.8)	15 (19.5)	
	Missing	11 (6.3)	5 (5.1)	6 (7.8)	

203

204 Table 1. Sociodemographic characteristics of the study population, including comparison between

205 groups that agreed and declined to join HPV self-sampling. IQR = Interquartile range.

206 Figure 2 and Table S1 show the responses for the major and minor reasons for not attending cervical
 207 cancer screening. The top three major reasons reported were that they were “afraid of getting a bad
 208 result” (16.1%, n = 28), “feeling embarrassed being examined by a doctor or nurse” (14.9%, n = 26),
 209 and “I can't find the time as I'm too busy at home” (10.3%, n = 18). The top three minor reasons
 210 were “feeling embarrassed being examined by a doctor or nurse” (20.7%, n = 36), “I can't find time
 211 as I'm too busy at work” (20.7%, n = 36), and “afraid of getting a bad result” (20.1%, n = 35).
 212



213
 214 Figure 2. Responses on their major and minor reasons for not attending cervical cancer screening,
 215 among non-attendees at JPSHC (Jan – Dec 2019). The x-axis indicates the percentage, and the
 216 number next to each bar indicates the actual number of responses.

217
 218
 219 When comparing top 10 major reasons for not attending screening between those who agreed and
 220 declined HPV self-sampling (Table 2), those whose major reason was “feeling embarrassed being

221 examined by a doctor or nurse” were significantly more likely to join self-sampling ($p = 0.020$). Also,
222 those whose major reason was “afraid of getting a bad result” were significantly more likely to
223 decline self-sampling ($p = 0.034$). Among those who were employed ($n = 98$), about a quarter (23.5%,
224 $n = 23$) reported work-related reasons as their major reason for not attending screening (“I can't find
225 the time as I'm too busy at work” and “Difficult to get permission from employer”).

226

No.	Top ten major reasons of screening non-attendance	Total n (%)	Joined HPV self-sampling n (%)	Declined HPV self-sampling n (%)	p-value
1	I feel embarrassed being examined by a doctor or nurse	26 (14.9)	20 (76.9)	6 (23.1)	0.020*
2	I am scared of pain because of previous bad experience(s)	16 (9.2)	8 (50.0)	8 (50.0)	0.825
3	I am scared of getting a bad result	28 (16.1)	10 (35.7)	18 (64.3)	0.034*
4	I can't find the time as I'm too busy at home	18 (10.3)	12 (66.7)	6 (33.3)	0.463
5	I can't find the time as I'm too busy at work	16 (9.2)	10 (62.5)	6 (37.5)	0.759
6	Difficult to get permission from employer	8 (4.6)	5 (62.5)	3 (37.5)	1
7	I have never heard of a Pap Test	7 (4.0)	4 (57.1)	3 (42.9)	1
8	I have forgotten about it	6 (3.4)	5 (83.3)	1 (16.7)	0.229
9	I did not receive any invitation	6 (3.4)	5 (83.3)	1 (16.7)	0.229
10	Others	15 (8.6)	7 (46.7)	8 (53.3)	0.492

227 Table 2. The top ten major reasons of not attending cervical cancer screening at JPSHC, Brunei

228 (Jan – Dec 2019), with comparison between those who agreed and declined HPV self-sampling.

229 Responses from 146 participants (83.9% of the total study population) were included.

230

231

232 While there is a variation in the responses when asked about their health and susceptibility to

233 disease, most agreed on the benefits of undergoing Pap test (92.0%, n = 160) and on the severity of

234 cervical cancer (82.8%, n = 144; Table 3).

235

236

No.	Attitude questions	Agree n (%)	Neutral n (%)	Disagree n (%)
1	I believe I am healthy and free of any diseases	62 (35.6)	61 (35.1)	51 (29.3)
2	Having Pap test taken is beneficial for my health	160 (92.0)	10 (5.7)	4 (2.3)
3	Like any women, I am susceptible to develop cervical cancer	110 (63.2)	52 (29.9)	12 (6.9)
4	Cervical cancer can be severe and may lead to death	144 (82.8)	23 (13.2)	7 (4.0)

237 Table 3. Attitudes towards cervical cancer screening among non-attendees at JPSHC, Brunei (Jan –
 238 Dec 2019). Responses from the total study population (n = 174) were included.

239

240

241 When comparing the responses for each attitude question between those who agreed and declined
 242 to join HPV self-sampling (Table 4), those who agreed that they are more susceptible to develop
 243 cervical cancer were significantly more likely to join HPV self-sampling ($p = 0.023$).

244

245

246

No.	Attitude questions		Joined HPV self-sampling n (%)	Declined HPV self-sampling n (%)	p-value
1	I believe I am healthy and free of any diseases	Agree	34 (54.8)	28 (45.2)	0.984
		Neutral/ Disagree	63 (56.3)	49 (43.7)	
2	Having Pap test taken is beneficial for my health	Agree	91 (56.9)	69 (43.1)	0.464
		Neutral/ Disagree	6 (42.9)	8 (57.1)	
3	Like any women, I am susceptible to develop cervical cancer	Agree	69 (62.7)	41 (37.3)	0.023*
		Neutral/ Disagree	28 (43.8)	36 (56.2)	
4	Cervical cancer can be severe and may lead to death	Agree	79 (54.9)	65 (45.1)	0.754
		Neutral/ Disagree	18 (60.0)	12 (40.0)	

247 Table 4. Comparison of the attitudes towards cervical cancer screening among non-attendees at

248 JPSHC, Brunei (Jan–Dec 2019), between those who agreed and declined HPV self-sampling.


249 Responses from the total study population (n = 174) were included.

250

251 Most participants responded that they would like to obtain more information about cervical cancer
 252 screening (85.6%, n = 149). The top preferred information sources were healthcare workers (59.8%,
 253 n = 104), social messaging platforms (28.7%, n = 50) and social media (26.4%, n = 46; Figure 3).

254

255



256

257 Figure 3. Preferred sources of information about cervical cancer among non-attendees at JPSHC,

258 Brunei (Jan–Dec 2019). The x-axis indicates the percentage, and the number next to each bar

259 indicates the number of responses. Multiple responses were allowed and responses from the total

260 study population (n = 174) were included.

261

262 Among those who participated in self-sampling (55.7%, n = 97), their responses on the use of the

263 self-sampling kit (Table 5) were generally positive and encouraging. A majority agreed that the

264 instructions were clear (94.8%, n = 92), that it was easy to perform the swab (93.8%, n = 91), and

265 that it was more convenient than the Pap test (91.7%, n = 89). They also reported their confidence in

266 correctly getting the sample (92.8%, n = 90), would prefer to use this method next time (94.8%, n =

267 92), and would recommend this method to other women (93.8%, n = 91). Notably, 54.6% (n = 53)

268 still prefer a proper Pap test for their subsequent check-up.

269

270

No.	Self-sampling Questions	Agree	Neutral	Disagree
-----	-------------------------	-------	---------	----------

		n (%)	n (%)	n (%)
1	I thought the instructions were clear	92 (94.8)	0 (0.0)	5 (5.2)
2	It was easy to do the swab	91 (93.8)	1 (1.0)	5 (5.2)
3	Taking the sample with the swab was painful	12 (12.4)	8 (8.2)	77 (79.4)
4	Taking the sample was uncomfortable to do	11 (11.4)	4 (4.1)	82 (84.5)
5	I felt embarrassed doing the self-sampling	9 (9.3)	1 (1.0)	87 (89.7)
6	It was convenient to do without having to undergo a Pap Test	89 (91.7)	3 (3.1)	5 (5.2)
7	I am confident I did it correctly	90 (92.8)	4 (4.1)	3 (3.1)
8	I want to use this method next time	92 (94.8)	2 (2.1)	3 (3.1)
9	I prefer to do this at home	64 (66.0)	15 (15.5)	18 (18.5)
10	I would recommend this method to other women	91 (93.8)	3 (3.1)	3 (3.1)
11	I trust that the result of this self-sampling will be accurate	74 (76.3)	19 (19.6)	4 (4.1)
12	I would like to attend for a proper Pap test in clinic next time	53 (54.6)	23 (23.7)	21 (21.7)

271 Table 5. Acceptability of HPV self-sampling among non-attendees who participated in HPV self-
 272 sampling at JPSHC, Brunei (Jan–Dec 2019). Responses from all respondents for Q2 (n = 97) were
 273 included.

274
 275 Among the 97 samples taken, nine (9.3%) tested positive for hr-HPV: one was positive for HPV 16
 276 and eight were positive for non-HPV 16/18 HPV genotype. Upon follow-up cytology, only one
 277 participant had a normal cytological test result, whilst another participant with non-16/18 HPV
 278 genotype was found to have CIN 3 with glandular involvement following a confirmatory biopsy. No
 279 significant differences were observed when comparing the sociodemographic characteristics
 280 between those who tested hr-HPV positive and those who tested hr-negative (Table S2).

281

282

283 **Discussion**

284

285 This two-part pilot study explored the reasons for cervical screening non-attendance among
286 Bruneian women and whether HPV self-sampling is a viable alternative for the non-attendees. Our
287 findings highlight three important points to consider for improving both screening uptake and
288 detection of cervical cancer.

289

290 First, our findings suggest that it is necessary to provide accurate information among Bruneian
291 women on cervical cancer, the importance of screening and addressing any misconceptions about
292 the Pap test. Important facts to relay include the slow development from pre-cancerous changes to
293 cervical cancer, that pre-cancerous changes are highly treatable, and that screening will help in early
294 detection and thus facilitate successful treatment. This is evident in our study, where emotional
295 barriers (fear of unfavourable test results and embarrassment) were the most common major
296 reasons of screening non-attendance. Many women have misconceptions about abnormal Pap test
297 results by relating them to cervical cancer diagnoses [23]. It is not surprising then that almost two-
298 thirds of the women who cited this as their main barrier declined to take part in HPV self-sampling
299 part. As our study participants are predominantly Malays and thus of Islamic faith, religious and
300 cultural modesty could also be a contributing factor for embarrassment among Muslim women [24].

301

302 Lack of information or knowledge has been suggested to reduce women's concerns towards cervical
303 cancer [25] and whether to continue attending cervical screening [26]. Although fear,
304 embarrassment and other psychosocial barriers may play a large role at the onset of screening
305 programme, its role diminishes over time with increasing education and knowledge of screening
306 [27]. Educational interventions could also benefit the small group of women who cited menopause,
307 cessation of child-bearing and having had HPV vaccination as reasons for not attending screening.

308

309 Promoting cervical cancer awareness could also impact non-attendees' decision to participate in
310 HPV self-sampling. In our study, we observed those who agree that they are susceptible to cervical

311 cancer were significantly more likely to participate in HPV self-sampling. This suggests that perceived
312 susceptibility could be an important factor for self-sampling participation, whereby those who do
313 not perceive themselves as susceptible were less likely to engage in preventative behaviours
314 [25,28,29]. Perceived susceptibility can be increased through education to improve their beliefs on
315 the necessity of screening [30]. We suggest that such information could be more effectively
316 disseminated as simple health messages endorsed by Brunei's Ministry of Health via website, social
317 media platforms, and the BruHealth application [31] developed by the Brunei government as a
318 public engagement tool during the COVID-19 pandemic.

319

320 Second, we observed high acceptability of HPV self-sampling among our participants. Indeed, meta-
321 analyses have indicated strong acceptance of self-sampling and a preference for the latter over
322 clinician sampling [32], mainly due to logistical reasons [33]. Implementing HPV self-sampling in
323 screening programmes have been shown to increase the screening uptake among non-attendees
324 [3,4,7], and also increases the detection of CIN 2+ lesions [8,9]. Providing HPV self-sampling as a
325 cervical cancer screening option could also encourage those, whose main reason for not attending
326 was fear of pain due to previous experience, to attend screening. This reason, also common in our
327 study, was reported as a factor for avoiding screening [34] and is suggested to predict future
328 screening uptake [35]. Among those who joined HPV self-sampling in our study, at least half cited
329 embarrassment, fear of pain or lack of time due to home and/or work commitments as their major
330 reason of not attending screening. This suggest that flexibility to accommodate women's screening
331 method preference [36], such as the option to carry out self-sampling [37], could improve screening
332 uptake.

333

334 Notably, only about three-quarters of our self-sampling participants were confident of the result
335 accuracy and less than two-thirds were willing to do the self-sampling at home, suggesting that
336 these participants could be doubting their technique and would prefer to do this in clinics instead.

337 Also, more than half of them were willing to undergo in-clinic Pap test for their subsequent testing.

338 This is an important consideration if cytology triaging is going to be the country's strategy as a

339 follow-up to HPV screening.

340

341 Thirdly, most of the detected hr-HPV genotypes in our study were non-16/18, with only one out of

342 nine participants tested positive for HPV 16. Even though our sample size is small, this result

343 suggests that it may not be accurate to assume HPV 16 or 18 as common hr-HPV genotypes in

344 Brunei, although this is true in the global context [38]. Other studies have detected a significant

345 percentage of non-16/18 hr-HPV genotypes, suggesting the presence of region-specific

346 heterogeneity in the HPV genotype distribution [38–42]. Also, variation in HPV distribution among

347 different ethnic groups has been reported in an American study [43], although reasons for these

348 differences are unclear. Our finding has potential implication on Brunei's national school-based HPV

349 vaccination programme which currently provides vaccines which do not confer protection against

350 non-16/18 genotypes. Providing vaccines that confers protection against nine hr-HPV genotypes [44]

351 could be a better alternative for Bruneian females. Larger population-based studies to understand

352 the distribution of HPV genotypes among Bruneian women will be crucial to determine the efficacy

353 or impact of the current vaccines.

354

355 A major limitation for this study is that non-attendees from only one health center were recruited,

356 thus our results are not representative of the adult female population in Brunei. Moreover, the

357 validity of our findings could be compromised due to the small sample size. Our study findings, even

358 at this pilot stage, could encourage stakeholders to conduct similar studies with larger population

359 coverage. Also, as this study relied on the self-reported history of previous Pap test attendance, we

360 might have missed recruiting those who may have forgotten their last Pap test date.

361

362 In conclusion, our findings indicate the need to further promote education and awareness towards
363 cervical cancer and its screening process. Reasons of cervical cancer screening non-attendance were
364 mainly related to emotional and logistical factors. As we found high acceptance towards HPV self-
365 sampling, this could be adopted as an alternative for women who refrain from Pap test. Our high
366 detection of non-16/18 HPV genotypes suggest high prevalence of other hr-HPV genotypes in
367 Brunei. Future larger studies involving more Bruneian women can be done to verify our results.
368 Follow-up studies should also be done to consider HPV testing as the suitable method for cervical
369 cancer screening.

370

371 **Acknowledgements**

372 The authors would like to thank the JPSHC staff who have assisted in participant recruitment and
373 questionnaire distribution.

374

375 **Funding**

376 Funding for this study was obtained from the Ministry of Health, Brunei Darussalam.

377

378 **Author contributions**

379 **Liling Chaw:** Conceptualization, Methodology, Data curation, Formal analysis, Supervision, Writing -
380 original draft, Writing - review & editing

381 **Shirley HF Lee:** Visualization, Writing - original draft, Writing - review & editing

382 **Nurul Iffah Hazwani Ja'afar:** Investigation, Data curation, Writing - original draft

383 **Edwin Lim:** Conceptualization, Methodology, Resources, Funding acquisition, Supervision, Writing -
384 review & editing

385 **Roslin Sharbawi:** Conceptualization, Methodology, Resources, Funding acquisition, Investigation,
386 Project administration, Supervision, Writing - original draft, Writing - review & editing

387

388 **References**

389

- 390 1. World Health Organization. Cervical cancer. 2018 [cited 10 Aug 2020]. Available:
391 https://www.who.int/health-topics/cervical-cancer#tab=tab_1
- 392 2. Gustafsson L, Pontén J, Zack M, Adami H-O. International incidence rates of invasive cervical
393 cancer after introduction of cytological screening. *Cancer Causes Control*. 1997;8: 755–763.
394 doi:10.1023/A:1018435522475
- 395 3. Yeh PT, Kennedy CE, Vuyst H de, Narasimhan M. Self-sampling for human papillomavirus
396 (HPV) testing: a systematic review and meta-analysis. *BMJ Glob Heal*. 2019;4: e001351.
397 doi:10.1136/BMJGH-2018-001351
- 398 4. Racey C, Withrow D, Gesink D. Self-collected HPV testing improves participation in cervical
399 cancer screening: a systematic review and meta-analysis. *Can J Public Health*. 2013;104:
400 e159-66. doi:10.1007/BF03405681
- 401 5. Maza M, Melendez M, Masch R, Alfaro K, Chacon A, Gonzalez E, et al. Acceptability of self-
402 sampling and human papillomavirus testing among non-attenders of cervical cancer
403 screening programs in El Salvador. *Prev Med (Baltim)*. 2018.
404 doi:10.1016/j.ypmed.2018.06.017
- 405 6. Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Retraite L Le, Djoufelkit K, et al. HPV self-
406 sampling or the Pap-smear: A randomized study among cervical screening nonattenders from
407 lower socioeconomic groups in France. *Int J Cancer*. 2013. doi:10.1002/ijc.28283
- 408 7. Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, Cuberli M, et al. Effect of self-
409 collection of HPV DNA offered by community health workers at home visits on uptake of
410 screening for cervical cancer (the EMA study): A population-based cluster-randomised trial.
411 *Lancet Glob Heal*. 2015;3: e85–e94. doi:10.1016/S2214-109X(14)70354-7
- 412 8. Gustavsson I, Aarnio R, Berggrund M, Hedlund-Lindberg J, Strand A-S, Sanner K, et al.
413 Randomised study shows that repeated self-sampling and HPV test has more than two-fold

- 414 higher detection rate of women with CIN2+ histology than Pap smear cytology. *Br J Cancer*.
415 2018;118: 896–904. doi:10.1038/bjc.2017.485
- 416 9. Arrossi S, Paolino M, Laudi R, Gago J, Campanera A, Marín O, et al. Programmatic human
417 papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in
418 Argentina: a population-based, before-and-after retrospective cohort study. *Lancet Glob
419 Heal*. 2019;7: e772–e783. doi:10.1016/S2214-109X(19)30048-8
- 420 10. Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical cancer screening
421 programs in Europe: The transition towards HPV vaccination and population-based HPV
422 testing. *Viruses*. 2018;10. doi:10.3390/v10120729
- 423 11. Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening on cervical cancer
424 mortality: Estimation using stage-specific results from a nested case-control study. *Br J
425 Cancer*. 2016;115: 1140–1146. doi:10.1038/bjc.2016.290
- 426 12. Canfell K, Sitas F, Beral V. Cervical cancer in Australia and the United Kingdom: Comparison of
427 screening policy and uptake, and cancer incidence and mortality. *Med J Aust*. 2006;185: 482–
428 486. doi:10.5694/j.1326-5377.2006.tb00661.x
- 429 13. Ministry of Health Brunei Darussalam. Health Information Booklet 2017 (Second Revision).
430 2019 [cited 11 Feb 2020]. Available: [http://moh.gov.bn/SitePages/Health Information
431 Booklet.aspx](http://moh.gov.bn/SitePages/Health%20Information%20Booklet.aspx)
- 432 14. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of
433 incidence and mortality of cervical cancer in 2018: a worldwide analysis. *Lancet Glob Heal*.
434 2020;8: e191–e203. doi:10.1016/S2214-109X(19)30482-6
- 435 15. Chaw LL, Lim STW, Md Yussof SR. Human Papillomavirus vaccine coverage among female
436 students in Brunei Darussalam: results from the first 4 years of the national school-based
437 vaccination programme. *Heliyon*. 2019;5. doi:10.1016/j.heliyon.2019.e02588
- 438 16. Peto PJ, Gilham PC, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has
439 prevented in the UK. *Lancet*. 2004;364: 249–256. doi:10.1016/S0140-6736(04)16674-9

- 440 17. Bosgraaf RP, Ketelaars PJW, Verhoef VMJ, Massuger LFAG, Meijer CJLM, Melchers WJG, et al.
441 Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in
442 Dutch women. *Prev Med (Baltim)*. 2014. doi:10.1016/j.ypmed.2014.04.011
- 443 18. Virtanen A, Nieminen P, Niironen M, Luostarinen T, Anttila A. Self-sampling experiences
444 among non-attendees to cervical screening. *Gynecol Oncol*. 2014;135: 487–494.
445 doi:10.1016/j.ygyno.2014.09.019
- 446 19. Bayu H, Berhe Y, Mulat A, Alemu A. Cervical Cancer Screening Service Uptake and Associated
447 Factors among Age Eligible Women in Mekelle Zone, Northern Ethiopia, 2015: A Community
448 Based Study Using Health Belief Model. Grce M, editor. *PLoS One*. 2016;11: e0149908.
449 doi:10.1371/journal.pone.0149908
- 450 20. Sultana F, Mullins R, English DR, Simpson JA, Drennan KT, Heley S, et al. Women’s experience
451 with home-based self-sampling for human papillomavirus testing. *BMC Cancer*. 2015;15: 849.
452 doi:10.1186/s12885-015-1804-x
- 453 21. The Hague: Health Council of the Netherlands. Health Council of the Netherlands Population
454 screening for cervical cancer. 2011;2011/07E. Available:
455 https://www.gezondheidsraad.nl/sites/default/files/201107E_PopulationSCC_0.pdf
- 456 22. R Core Team. R: A language and environment for statistical computing. R Foundation for
457 Statistical Computing, Vienna, Austria; 2020. Available: <http://www.r-project.org/>
- 458 23. Fylan F. Screening for cervical cancer: a review of women’s attitudes, knowledge, and
459 behaviour. *Br J Gen Pract*. 1998;48: 1509–14.
- 460 24. Ali S, Skirton H, Clark MT, Donaldson C. Integrative review of cervical cancer screening in
461 Western Asian and Middle Eastern Arab countries. *Nurs Heal Sci*. 2017;19: 414–426.
462 doi:10.1111/nhs.12374
- 463 25. Agurto I, Arrossi S, White S, Coffey P, Dzuba I, Bingham A, et al. Involving the community in
464 cervical cancer prevention programs. *Int J Gynaecol Obstet*. 2005;89 Suppl 2: S38-45.
465 doi:10.1016/j.ijgo.2005.01.015

- 466 26. Chorley AJ, Marlow LA V, Forster AS, Haddrell JB, Waller J. Experiences of cervical screening
467 and barriers to participation in the context of an organised programme: a systematic review
468 and thematic synthesis. *Psychooncology*. 2017;26: 161–172. doi:10.1002/pon.4126
- 469 27. Teng FF, Mitchell SM, Sekikubo M, Biryabarema C, Byamugisha JK, Steinberg M, et al.
470 Understanding the role of embarrassment in gynaecological screening: A qualitative study
471 from the ASPIRE cervical cancer screening project in Uganda. *BMJ Open*. 2014.
472 doi:10.1136/bmjopen-2014-004783
- 473 28. Shirazi Zadeh Mehraban S, Namdar A, Naghizadeh MM. Assessment of Preventive Behavior
474 for Cervical Cancer with the Health Belief Model. *Asian Pac J Cancer Prev*. 2018;19: 2155–
475 2163. doi:10.22034/APJCP.2018.19.8.2155
- 476 29. Tapera R, Manyala E, Erick P, Maswabi TM, Tumoyagae T, Letsholo B, et al. Knowledge and
477 Attitudes towards Cervical Cancer Screening amongst University of Botswana Female
478 Students. *Asian Pac J Cancer Prev*. 2017;18: 2445–2450. doi:10.22034/APJCP.2017.18.9.2445
- 479 30. Khademolhosseini F, Noroozi A, Tahmasebi R. The Effect of Health Belief Model-Based
480 Education through Telegram Instant Messaging Services on Pap smear performance. *Asian
481 Pac J Cancer Prev*. 2017;18: 2221–2226. doi:10.22034/APJCP.2017.18.8.2221
- 482 31. Ministry of Health Brunei. BruHealth. 2020 [cited 21 Dec 2020]. Available:
483 <http://www.moh.gov.bn/SitePages/bruhealth.aspx>
- 484 32. Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of self-sampled
485 screening for HPV DNA: A systematic review and meta-analysis. *Sexually Transmitted
486 Infections*. 2017. doi:10.1136/sextrans-2016-052609
- 487 33. Lorenzi NPC, Termini L, Longatto Filho A, Tacla M, de Aguiar LM, Beldi MC, et al. Age-related
488 acceptability of vaginal self-sampling in cervical cancer screening at two university hospitals:
489 a pilot cross-sectional study. *BMC Public Health*. 2019;19: 963. doi:10.1186/s12889-019-
490 7292-1
- 491 34. Ebu NI, Mupepi SC, Siakwa MP, Sampselle CM. Knowledge, practice, and barriers toward

- 492 cervical cancer screening in Elmina, Southern Ghana. *Int J Womens Health*. 2015;7: 31–39.
493 doi:10.2147/IJWH.S71797
- 494 35. Seow A, Wong ML, Smith WCS, Lee HP. Beliefs and Attitudes as Determinants of Cervical
495 Cancer Screening: A Community-Based Study in Singapore. *Preventive Medicine*. 1995. pp.
496 134–141. doi:10.1006/pmed.1995.1026
- 497 36. Bansil P, Wittet S, Lim JL, Winkler JL, Paul P, Jeronimo J. Acceptability of self-collection
498 sampling for HPV-DNA testing in low-resource settings: a mixed methods approach. *BMC*
499 *Public Health*. 2014;14: 596. doi:10.1186/1471-2458-14-596
- 500 37. Jeronimo J, Perkins RB, Scalici J, Pierce JY. Should Self-Sampling Be an Option for Women in
501 the United States? *J Low Genit Tract Dis*. 2019;23: 54. doi:10.1097/LGT.0000000000000453
- 502 38. Albawardi A, Quddus MR, Al Awar S, Almarzooqi S. Frequency of rare and multi viral high-risk
503 HPV types infection in cervical high grade squamous intraepithelial lesions in a non-native
504 dominant middle eastern country: A polymerase chain reaction-based pilot study. *Diagn*
505 *Pathol*. 2018. doi:10.1186/s13000-018-0716-x
- 506 39. Zeng Z, Yang H, Li Z, He X, Griffith CC, Chen X, et al. Prevalence and Genotype Distribution of
507 HPV Infection in China: Analysis of 51,345 HPV Genotyping Results from China’s Largest CAP
508 Certified Laboratory. *J Cancer*. 2016. doi:10.7150/jca.14971
- 509 40. Khoo SP, Bhoo-Pathy N, Yap SH, Anwar Shafii MK, Hairizan Nasir N, Belinson J, et al.
510 Prevalence and sociodemographic correlates of cervicovaginal human papillomavirus (HPV)
511 carriage in a cross-sectional, multiethnic, community-based female Asian population. *Sex*
512 *Transm Infect*. 2018. doi:10.1136/sextrans-2017-053320
- 513 41. Peng RR, Li HM, Chang H, Li JH, Wang AL, Chen XS. Prevalence and genotype distribution of
514 cervical human papillomavirus infection among female sex workers in Asia: A systematic
515 literature review and meta-analysis. *Sexual Health*. 2012. doi:10.1071/SH11066
- 516 42. Al-Awadhi R, Chehadeh W, Jaragh M, Al-Shaheen A, Sharma P, Kapila K. Distribution of
517 human papillomavirus among women with abnormal cervical cytology in Kuwait. *Diagn*

- 518 Cytopathol. 2013. doi:10.1002/dc.21778
- 519 43. Keller MJ, Burk RD, Massad LS, Eltoun IE, Hessol NA, Anastos K, et al. Racial differences in
520 human papilloma virus types amongst United States women with HIV and cervical precancer.
521 AIDS. 2018. doi:10.1097/QAD.0000000000002005
- 522 44. Yusupov A, Popovsky D, Mahmood L, Kim AS, Akman AE, Yuan H. The nonavalent vaccine: a
523 review of high-risk HPVs and a plea to the CDC. Am J Stem Cells. 2019.
- 524
- 525
- 526

527 **Supplementary information**

528

529 Table S1. Responses on their major and minor reasons for not attending cervical cancer screening

530 among non-attendees at JPSHC, Brunei (Jan – Dec 2019)

531

No.	Reasons for not attending screening	Major reason* n (%)	Minor reason^ n (%)
1	I feel embarrassed being examined by a doctor or nurse	26 (14.9)	36 (20.7)
2	I am scared of pain because of previous bad experience(s)	16 (9.2)	13 (7.5)
3	I am afraid of getting a bad result	28 (16.1)	35 (20.1)
4	I can't find the time as I'm too busy at home	18 (10.3)	28 (16.1)
5	I can't find the time as I'm too busy at work	16 (9.2)	36 (20.7)
6	Nobody to send me to clinic	2 (1.2)	11 (6.3)
7	Nobody is looking after child(ren) at home	2 (1.2)	13 (7.5)
8	Difficult to get permission from employer	8 (4.6)	14 (8.1)
9	I have never heard of a Pap Test	7 (4.0)	8 (4.6)
10	I don't know what cervical cancer is	1 (0.6)	15 (8.6)
11	Not necessary as I am healthy	4 (2.3)	15 (8.6)
12	Not necessary as I am not child-bearing anymore	4 (2.3)	14 (8.0)
13	Not necessary as I don't have menses anymore	4 (2.3)	11 (6.3)
14	Not necessary as I don't have a partner anymore	0 (0.0)	1 (0.6)
15	Not necessary as I have already had my HPV vaccination	2 (1.2)	2 (1.2)
16	I have forgotten about it	6 (3.4)	2 (1.2)
17	I did not receive any invitation	6 (3.4)	0 (0.0)
18	Others	15 (8.6)	4 (2.3)
	Missing	9 (5.1)	0 (0.0)

*One response for each participant

^Multiple responses were allowed

532

533

534

535

536

537 Table S2. Socio demographic characteristics and comparison between screening non-attendees who

538 tested positive and negative for hr-HPV at JPSHC, Brunei (Jan – Dec 2019),

539

Characteristics		Total study population (n = 174) n (%)	Joined self-sampling (n = 97) n (%)	HPV positive (n = 9) n (%)	HPV negative (n = 88) n (%)	p-value
Median age in years (IQR)		45 (15.25)	41.0 (17)	35.0 (10)	41.5 (16.5)	0.115
Age-group	20 - 24	3 (1.7)	3 (3.1)	0 (0.0)	3 (3.4)	0.637
	25 - 29	20 (11.5)	15 (15.5)	3 (33.4)	12 (13.6)	
	30 - 34	14 (8.1)	10 (10.3)	1 (11.1)	9 (10.2)	
	35 - 39	28 (16.1)	18 (18.5)	3 (33.4)	15 (17.1)	
	40 - 44	18 (10.3)	11 (11.3)	0 (0.0)	11 (12.5)	
	45 - 49	27 (15.5)	12 (12.4)	1 (11.1)	11 (12.5)	
	50 - 54	35 (20.1)	15 (15.5)	0 (0.0)	15 (17.1)	
	55 - 59	14 (8.1)	10 (10.3)	1 (11.1)	9 (10.2)	
	> 60	13 (7.5)	3 (3.1)	0 (0.0)	3 (3.4)	
	Missing	2 (1.1)	0 (0.0)	0 (0.0)	0 (0.0)	
Race	Malay	161 (92.5)	90 (92.8)	8 (88.8)	82 (93.2)	0.289
	Chinese	6 (3.5)	4 (4.1)	0 (0.0)	4 (4.5)	
	Other	7 (4.0)	3 (3.1)	1 (11.1)	2 (2.3)	
Education level	Primary school	16 (9.2)	10 (10.3)	2 (22.2)	8 (9.1)	0.456
	Secondary school	96 (55.2)	49 (50.5)	4 (44.5)	45 (51.1)	
	College / university	57 (32.7)	35 (36.1)	3 (33.3)	32 (36.4)	
	Missing	5 (2.9)	3 (3.1)	0 (0.0)	3 (3.4)	
Marital status	Married	157 (90.2)	91 (93.8)	9 (100)	82 (93.2)	1
	Divorced	8 (4.6)	2 (2.1)	0 (0.0)	2 (2.3)	
	Widowed	9 (5.2)	4 (4.1)	0 (0.0)	4 (4.5)	
Occupation	Housewife	64 (36.8)	39 (40.2)	5 (55.6)	34 (38.6)	0.862
	Government employee	67 (38.5)	41 (42.3)	3 (33.3)	38 (43.2)	
	Private employee	31 (17.8)	13 (13.4)	1 (11.1)	12 (13.6)	
	Retired	9 (5.2)	3 (3.1)	0 (0.0)	3 (3.4)	
	Unemployed	1 (0.6)	1 (1.0)	0 (0.0)	1 (1.2)	
	Other	2 (1.1)	0 (0.0)	0 (0.0)	0 (0.0)	
Household income	< \$500	27 (15.5)	15 (15.5)	1 (11.1)	14 (15.9)	0.612
	\$500 < \$999	27 (15.5)	12 (12.4)	0 (0.0)	12 (13.6)	

	\$1000-\$1999	40 (23.0)	22 (22.7)	3 (33.3)	19 (21.6)	
	\$2000-\$2999	19 (10.9)	14 (14.3)	0 (0.0)	14 (15.9)	
	\$3000-\$5000	24 (13.8)	15 (15.5)	2 (22.3)	13 (14.8)	
	>\$5000	3 (1.7)	2 (2.1)	0 (0.0)	2 (2.3)	
	Missing	34 (19.5)	17 (17.5)	3 (33.3)	14 (15.9)	
No of births	0	27 (15.5)	17 (17.5)	3 (33.3)	14 (15.9)	0.453
	1	19 (10.9)	14 (14.4)	1 (11.1)	13 (14.8)	
	2	22 (12.1)	14 (14.4)	0 (0.0)	14 (15.9)	
	3 or more	105 (60.3)	51 (52.6)	5 (55.6)	46 (52.3)	
	Missing	2 (1.2)	1 (1.1)	0 (0.0)	1 (1.1)	
Last Pap test done	Never	41 (23.6)	29 (29.9)	4 (44.4)	25 (28.4)	0.313
	4-10 years	91 (52.3)	48 (49.5)	4 (44.4)	44 (50.0)	
	> 10 years	36 (20.7)	15 (15.5)	0 (0.0)	15 (17.1)	
	Missing	6 (3.4)	5 (5.1)	1 (11.2)	4 (4.5)	
Completed HPV vaccination	Never	95 (54.6)	50 (51.6)	6 (66.7)	44 (50.0)	0.899
	Yes	27 (15.5)	16 (16.5)	1 (11.1)	15 (17.1)	
	No	41 (23.6)	26 (26.8)	2 (22.2)	24 (27.3)	
	Missing	11 (6.3)	5 (5.1)	0 (0.0)	5 (5.6)	

540